RXST STOCK NEWS: RxSight, Inc. Investors Urged to Act by September 22 Court Deadline -- Contact BFA Law if You Suffered Losses

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Financial Performance - RxSight experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors despite the company promoting strong sales [4]. - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, leading to a 38% drop in stock price from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulted in another 38% decline in stock price from $12.79 to $7.95 per share [6].